The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clonal hematopoiesis in survivors of childhood cancer.
 
Danielle Novetsky Friedman
Consulting or Advisory Role - Fennec Pharma
Patents, Royalties, Other Intellectual Property - Royalties for UptoDate contribution
 
Irenaeus Chi-Chung Chan
No Relationships to Disclose
 
Chaya S. Moskowitz
No Relationships to Disclose
 
Shanita Li
No Relationships to Disclose
 
Kimberly Turner
No Relationships to Disclose
 
Jie Liu
No Relationships to Disclose
 
Nancy Bouvier
No Relationships to Disclose
 
Michael Francis Walsh
No Relationships to Disclose
 
Barbara Spitzer
No Relationships to Disclose
 
Andrew Kung
Leadership - Isabl Technologies
Stock and Other Ownership Interests - Imago Pharma; Isabl Technologies
Consulting or Advisory Role - DarwinHealth; Emendo; Imago Pharma; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Licensing and royalty from bioluminescence imaging models
 
Michael F. Berger
Consulting or Advisory Role - AstraZeneca; Lilly; PetDx
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Megan A. Cooper
Stock and Other Ownership Interests - Adapta (I); Orca Bio (I); WUGEN, Inc. (I)
Consulting or Advisory Role - Affimed Therapeutics (I); AI proteins (I); Enzyvant; Pharming NV; Simcha Therapeutics (I); Smart Immune (I); WUGEN, Inc. (I)
Research Funding - Afimed (I); HCW Biologics (I)
 
Iskra Pusic
Consulting or Advisory Role - Incyte; Kadmon; Syndax
 
Geoffrey L. Uy
Consulting or Advisory Role - Jazz Pharmaceuticals; Novartis
 
Daniel C Link
No Relationships to Disclose
 
Todd E Druley
Employment - Mission Bio
Leadership - Mission Bio
 
Luis A. Diaz
Leadership - Epitope Diagnostics; Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Epitope Diagnostics; Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Other Relationship - Blackstone; Innovatus Capital Partners
 
Ross L. Levine
Leadership - Qiagen
Stock and Other Ownership Interests - Ajax; Anovia; Auron Therapeutics; BAKX Therapeutics; C4 Therapeutics; Epiphanes; Imago Pharma; IsoPlexis; Kurome Therapeutics; Loxo; Mana Therapeutics; Mission Bio; Prelude Therapeutics; Qiagen; Scorpion Therapeutics; Syndax; Zentalis
Honoraria - Amgen; Celgene; Genome Canada; Gilead Sciences; Incyte; Janssen; Lilly; The Mark Foundation For Cancer Research
Consulting or Advisory Role - BMS; Bridge Medicines; Bridge Therapeutics; Bridgebio; C4 Therapeutics; Celgene; Daiichi; Imago Pharma; IsoPlexis; Jubilant Biosys; Loxo; MorphoSys; Novartis; Prelude Therapeutics; Roche; Stelexis Therapeutics; Vida Ventures
Speakers' Bureau - Amgen; Lilly
Research Funding - Celgene; Cure Breast Cancer Foundation; ECOG-ACRIN; Prelude Therapeutics; Roche; The Mark Foundation For Cancer Research
Travel, Accommodations, Expenses - Auron Therapeutics; C4 Therapeutics; Constellation Pharmaceuticals; Genome Canada; Incyte; Qiagen
 
Neerav Shukla
Consulting or Advisory Role - Illumina
 
KELLY L BOLTON
Honoraria - Mission Bio
Consulting or Advisory Role - GoodCell
Research Funding - Bristol Myers Squibb Foundation; SERVIER